Eman Adel Saad
Lecturer
Diagnostic Value of Human Trophoblastic Transmembrane Glycoprotein (TROP-2) Expression in Diagnosing Papillary Thyroid Carcinoma Immunohistochemical Study
• 2026
Publication Information
Authors
Shimaa K. Abdelwahab a
, Ahmed E. Badawy a
, Nada M. Abdelhakiem a
,
Amr F. El-Sebaaie b
, Eman A. Saad a
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
ackground: Characteristic histopathological characteristics are
what determine the diagnosis of papillary thyroid carcinoma
(PTC). In some instances, immunohistochemical markers may be
necessary due to the presence of inconsistent features. It has been
reported that IHC stains, including HBME-1, galectin-3, and
CK19, are helpful in the diagnosis of PTC; however, the
sensitivity and specificity of these stains vary. TROP-2 is a new
and potential marker for PTC diagnosis, according to recent
research. Aim: This study aimed to investigate the significance of
TROP-2 expression in the diagnosis of PTC and its distinction
from benign thyroid lesions and low-risk neoplasms (NIFTP).
Material and methods: This retrospective study was carried out
on fifty-one cases classified according to the fifth edition of the
WHO classification 2022 as follows: thirteen benign thyroid
lesion cases, twelve low-risk neoplasms (NIFTP) cases, and
twenty-six papillary thyroid carcinoma cases. Six cases of breast
carcinoma were taken as a control. Clinicohistopathological
parameters were correlated with TROP-2 expression. Results: In
the current study, there was a positive, significant statistical
correlation(P
what determine the diagnosis of papillary thyroid carcinoma
(PTC). In some instances, immunohistochemical markers may be
necessary due to the presence of inconsistent features. It has been
reported that IHC stains, including HBME-1, galectin-3, and
CK19, are helpful in the diagnosis of PTC; however, the
sensitivity and specificity of these stains vary. TROP-2 is a new
and potential marker for PTC diagnosis, according to recent
research. Aim: This study aimed to investigate the significance of
TROP-2 expression in the diagnosis of PTC and its distinction
from benign thyroid lesions and low-risk neoplasms (NIFTP).
Material and methods: This retrospective study was carried out
on fifty-one cases classified according to the fifth edition of the
WHO classification 2022 as follows: thirteen benign thyroid
lesion cases, twelve low-risk neoplasms (NIFTP) cases, and
twenty-six papillary thyroid carcinoma cases. Six cases of breast
carcinoma were taken as a control. Clinicohistopathological
parameters were correlated with TROP-2 expression. Results: In
the current study, there was a positive, significant statistical
correlation(P